Alembic Pharma

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 24-Jun, Alembic Pharmaceuticals Ltd. is seeing a slight rise in stock price at 780.65, but it has declined 7.96% year-to-date and 17.23% over the past year, indicating poor long-term growth prospects despite recent positive performance and strong debt servicing ability.

As of 24-Jun, Alembic Pharmaceuticals Ltd. is experiencing a slight rise in its stock price, currently at 780.65, with a change of 4.1 (0.53%) upwards. This increase can be attributed to several factors. The stock has outperformed its sector by 0.8% today, indicating a positive performance relative to its peers. Additionally, the stock is trading above its 5-day, 20-day, 50-day, and 100-day moving averages, which often suggests a bullish trend.<BR><BR>However, it is important to note that despite the recent uptick, the stock has faced significant challenges over the longer term. Year-to-date, it has declined by 7.96%, and over the past year, it has fallen by 17.23%, which is considerably worse than the broader market's decline of 6.17%. The company's operating profit has also seen a negative annual growth rate of 9.97% over the last five years, indicating poor long-term growth prospects.<BR><BR>On a positive note, the company has a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.28 times, and its profits have risen by 28.2% over the past year, despite the stock's decline. The PEG ratio of 0.7 suggests that the stock may be undervalued compared to its earnings growth. Furthermore, high institutional holdings at 20.41% may provide some stability, as these investors typically have better resources to analyze company fundamentals.<BR><BR>In summary, while Alembic Pharmaceuticals Ltd. is currently seeing a rise in its stock price, the overall trend remains concerning due to its poor long-term growth and significant declines over the past year.

Which are the latest news on Alembic Pharma?

What does Alembic Pharma do?

Alembic Pharmaceuticals Ltd. is a small-cap company that manufactures and markets generic pharmaceutical products globally. As of March 2026, it reported net sales of 1,848 Cr and a net profit of 203 Cr, with a market cap of INR 14,566 Cr.

Overview:<BR>Alembic Pharmaceuticals Ltd. manufactures and markets generic pharmaceutical products globally and operates within the Pharmaceuticals & Biotechnology industry as a small-cap company.<BR><BR>History:<BR>Alembic Pharmaceuticals Ltd. was incorporated on June 16, 2010, as a wholly owned subsidiary of Alembic Ltd. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,848 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 203 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 14,566 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 20.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.51% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 12.93% <BR>Price to Book: 2.53 <BR><BR>Contact Details:<BR>Address: Alembic Road, Vadodara Gujarat: 390003 <BR>Phone: 91-0265-2280550 <BR>Email: apl.investors@alembic.co.in <BR>Website: http://www.alembicpharmaceuticals.com

How big is Alembic Pharma?

As of 10th June, Alembic Pharmaceuticals Ltd. has a market capitalization of 14,566.00 Cr, with recent net sales of 7,344.90 Cr and a net profit of 674.76 Cr.

As of 10th June, Alembic Pharmaceuticals Ltd. has a market capitalization of 14,566.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Alembic Pharmaceuticals reported Net Sales of 7,344.90 Cr and a Net Profit of 674.76 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 5,190.94 Cr and Total Assets of 7,606.90 Cr.

Who are in the management team of Alembic Pharma?

The management team of Alembic Pharma includes Chirayu R Amin (Chairman & CEO), Pranav Amin and Shaunak Amin (Managing Directors), Rajkumar Baheti (CFO), and Manisha Saraf (Company Secretary). The board also features several independent directors, contributing to the company's strategic direction and regulatory compliance.

The management team of Alembic Pharma includes the following key individuals:<BR><BR>1. **Chirayu R Amin** - Chairman & CEO<BR>2. **Pranav Amin** - Managing Director<BR>3. **Shaunak Amin** - Managing Director<BR>4. **Rajkumar Baheti** - Director (Finance) & CFO<BR>5. **Manisha Saraf** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- **Pranav N Parikh**<BR>- **K G Ramanathan**<BR>- **Paresh Saraiya**<BR>- **Archana Hingorani**<BR>- **Ashok Barat**<BR>- **Jai S Diwanji**<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Alembic Pharma?

Alembic Pharma's peers include Granules India, Caplin Point Lab, Natco Pharma, and Shilpa Medicare, among others. Granules India leads with a 1-year return of 45.45%, while Alembic Pharma has a return of -25.33%.

Peers: The peers of Alembic Pharma are Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Jubilant Pharmo, Concord Biotech, Alivus Life, Marksans Pharma, Viyash Scientifi, and Shilpa Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Granules India, Caplin Point Lab, Natco Pharma, Concord Biotech, Alivus Life, Marksans Pharma, and Alembic Pharma, while Average management risk is found at Cohance Life and Viyash Scientifi. Good growth is noted at none of the peers, while Below Average growth is seen at all peers except for Shilpa Medicare, which has Below Average growth as well. Excellent capital structure is present in Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Average capital structure is noted at Jubilant Pharmo and Below Average at Viyash Scientifi and Shilpa Medicare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Granules India at 45.45%, while Cohance Life has the lowest at -57.75%. Alembic Pharma's 1-year return of -25.33% is better than Cohance Life's but worse than Granules India's. Additionally, Cohance Life, Natco Pharma, Jubilant Pharmo, Concord Biotech, and Shilpa Medicare have negative six-month returns.

Are Alembic Pharmaceuticals Ltd. latest results good or bad?

Alembic Pharmaceuticals Ltd.'s latest results show a net profit increase of 52.44% to ₹202.70 crores, but this was boosted by an unusual tax credit. However, net sales declined by 1.52% and operating margins fell to a low of 12.34%, indicating underlying operational challenges, so investors should proceed with caution.

Alembic Pharmaceuticals Ltd.'s latest results present a mixed picture. On one hand, the company reported a net profit of ₹202.70 crores for Q4 FY26, which is a significant increase of 52.44% compared to the previous quarter. This growth in net profit is encouraging; however, it is important to note that this figure was largely influenced by an unusual tax credit that inflated profits.<BR><BR>On the other hand, the company's net sales declined by 1.52% quarter-on-quarter to ₹1,847.72 crores, indicating a concerning trend in revenue generation. Additionally, the operating margin fell to 12.34%, the lowest in eight quarters, reflecting challenges in cost management and operational efficiency. The return on equity (ROE) averaged only 11.80%, which is below industry standards, raising concerns about the company's ability to generate adequate returns on shareholder capital.<BR><BR>Overall, while the headline profit growth appears positive, the underlying operational challenges and declining margins suggest that the results are not entirely favorable. Investors may want to approach with caution, considering the potential risks associated with the company's current financial health and operational performance.

Should I buy, sell or hold Alembic Pharmaceuticals Ltd.?

Is Alembic Pharma technically bullish or bearish?

As of December 1, 2025, Alembic Pharma's technical outlook is bearish, driven by negative indicators such as a bearish MACD, moving averages, and KST, with no signs of bullish momentum from the RSI.

As of 1 December 2025, the technical trend for Alembic Pharma has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Both Bollinger Bands and the monthly MACD are mildly bearish, indicating a continuation of negative momentum. The RSI shows no signals on both weekly and monthly time frames, suggesting a lack of bullish momentum. Overall, the technical outlook remains negative.

How has been the historical performance of Alembic Pharma?

Alembic Pharma has shown consistent growth in net sales, reaching 6,672.08 Cr in March 2025, but profit after tax declined to 581.14 Cr. Total assets increased to 7,606.90 Cr, while cash flow from operating activities significantly dropped to 87.00 Cr, indicating potential cash management challenges.

Answer:<BR>The historical performance of Alembic Pharma shows a trend of increasing net sales and total operating income over the years, with net sales reaching 6,672.08 Cr in March 2025, up from 6,228.63 Cr in March 2024 and 5,652.62 Cr in March 2023. The total expenditure has also risen, amounting to 5,663.84 Cr in March 2025, compared to 5,295.27 Cr in March 2024. Operating profit, excluding other income, was 1,008.24 Cr in March 2025, reflecting a steady increase from 933.36 Cr in March 2024. However, profit after tax showed a slight decline to 581.14 Cr in March 2025 from 616.80 Cr in March 2024. The company's total assets increased to 7,606.90 Cr in March 2025, up from 6,275.94 Cr in March 2024, while total liabilities also rose to 7,606.90 Cr in March 2025, compared to 6,275.94 Cr in March 2024. Cash flow from operating activities decreased significantly to 87.00 Cr in March 2025 from 803.00 Cr in March 2024, indicating a shift in cash generation capabilities.<BR><BR>Breakdown:<BR>Alembic Pharma's financial performance has demonstrated a consistent growth trajectory in net sales, which increased from 5,305.79 Cr in March 2022 to 6,672.08 Cr in March 2025. This growth in sales has been accompanied by rising total operating income, which reached 6,672.08 Cr in March 2025. Despite this increase, the total expenditure also rose, leading to an operating profit of 1,008.24 Cr in March 2025, an improvement from the previous year. However, profit after tax saw a decrease to 581.14 Cr in March 2025, down from 616.80 Cr in March 2024. The company's total assets grew significantly to 7,606.90 Cr in March 2025, reflecting a robust asset base, while total liabilities increased correspondingly. The cash flow from operating activities, however, faced a notable decline, indicating potential challenges in cash management despite the overall growth in sales and assets.

Is Alembic Pharma overvalued or undervalued?

As of November 6, 2025, Alembic Pharma is considered very attractive and undervalued compared to peers, with a PE ratio of 28.37 and a PEG ratio of 0.00, indicating strong growth potential despite recent stock performance declines.

As of 6 November 2025, Alembic Pharma's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its valuation outlook. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 28.37, an EV to EBITDA of 27.19, and a Price to Book Value of 0.34, which highlight its potential for growth relative to its market price.<BR><BR>In comparison to its peers, Alembic Pharma's valuation stands out; for instance, Sun Pharma has a PE ratio of 35.02 and Divi's Lab is at 79.09, both categorizing them as expensive. Additionally, while Alembic Pharma's PEG ratio is 0.00, indicating no growth premium, competitors like Cipla and Dr. Reddy's Labs have PEG ratios of 1.25 and 2.15, respectively, suggesting that Alembic may offer better value. Despite a recent decline in stock performance relative to the Sensex over the past year, the company's strong fundamentals and attractive valuation metrics position it favorably in the market.

When is the next results date for Alembic Pharma?

The next results date for Alembic Pharma is 04 November 2025.

The next results date for Alembic Pharma is scheduled for 04 November 2025.

Who are the top shareholders of the Alembic Pharma?

The top shareholders of Alembic Pharma include Nirayu Limited with 35.64%, mutual funds holding 9.2%, foreign institutional investors at 3.94%, and DSP Midcap Fund as the largest public shareholder with 4.6%. Individual investors own 7.07% of the total shares.

The top shareholders of Alembic Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nirayu Limited, which owns 35.64% of the company. Additionally, mutual funds collectively hold 9.2% through 21 different schemes, while foreign institutional investors (FIIs) account for 3.94% with 151 FIIs involved. The highest public shareholder is DSP Midcap Fund, holding 4.6%. Individual investors also have a stake, representing 7.07% of the total shares.

Has Alembic Pharma declared dividend?

Yes, Alembic Pharmaceuticals Ltd. has declared a 550% dividend, amounting to ₹11 per share, with an ex-date of July 15, 2024. While recent performance shows mixed returns, the company has demonstrated positive total returns over the 2-year (81.26%) and 5-year (20.15%) periods.

Alembic Pharmaceuticals Ltd. has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 11<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 1.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.25%, with no dividend return, resulting in a total return of -9.25%.<BR><BR>Over the past year, the price return was 10.07%, with a dividend return of 1.23%, leading to a total return of 11.3%.<BR><BR>In the 2-year period, the price return was 78.15%, with a dividend return of 3.11%, culminating in a total return of 81.26%.<BR><BR>For the 3-year period, the price return was 34.58%, with a dividend return of 4.03%, resulting in a total return of 38.61%.<BR><BR>In the last 4 years, the price return was 3.58%, with a dividend return of 4.30%, giving a total return of 7.88%.<BR><BR>Over the past 5 years, the price return was 15.37%, with a dividend return of 4.78%, leading to a total return of 20.15%.<BR><BR>Overall, Alembic Pharmaceuticals has declared a significant dividend, and while the recent performance shows mixed returns, the longer-term total returns indicate a positive trend, particularly over the 2-year and 5-year periods.